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The prevalence of impaired kidney function has been estimated
to be between 10% and 20% of adult populations in most coun-
tries worldwide. Reduced kidney function has been recognized
as a risk factor for poor outcomes, and thus requires attention.
Key aspects of management of CKD have been defined for
referred populations, but not necessarily for those unreferred.
In order to improve patient outcomes, there is a need to take
a more holistic approach to the problem, by coordinating the
efforts of policy makers, those involved in health care system
redesign, clinicians, and researchers. In so doing, there should
be an improvement in both identification and management of
patients with impaired kidney function, whether cared for by
primary care physicians, specialists, or nephrologists, and irre-
spective of the health care system.
Reduced kidney function is increasingly recognized as
a risk factor for poor outcomes in all populations [1, 2].
Furthermore, estimates from numerous countries have
identified kidney dysfunction as highly prevalent and thus
of concern to health care planners, providers, and pa-
tients. The high prevalence of kidney disease mirrors the
increasing age, cardiovascular disease (CVD), and dia-
betes prevalence in our societies [3, 4], and thus has been
deemed an ‘epidemic’ in conjunction with those other
conditions.
Because of the uniformly poor outcomes of those with
chronic kidney disease (CKD), many have advocated for
the improved management of kidney disease. This arti-
cle aims to define optimal and coordinated management
of kidney disease and the rationale behind the need for
changes in care delivery for CKD. Specifically, we de-
scribe the need for strategies to help identify persons with
impaired kidney function at earlier stages and for educa-
tion of patients, primary care providers, and specialists, as
well as what is currently known to be effective in the man-
agement of this patient group. Furthermore, we suggest
that a coordinated effort that involves changes at the level
of public policy, education, clinical care, and research is
needed to ultimately improve patient outcomes.
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THE CURRENT SITUATION
High rates of adverse outcomes
The outcomes of patients with reduced glomerular fil-
tration rate (GFR) are uniformly poor [1, 2]. Patients with
CKD are more likely to die than go onto dialysis [5, 6].
This is thought to be due, in part, to lack of recognition of
CKD and therefore lack of delivery of optimal care in a
timely manner. In patients with GFR <60 mL/min, there
is an increased risk of death and cardiovascular events [1,
2]. These publications, in addition to those in the CVD
literature [7–9] which identify reduced GFR as an inde-
pendent risk factor for death or de novo events, add cred-
ibility to the need for reporting GFR instead of creatinine
alone and to aid interpretation, and thus identification of
risk.
Low rates of identification. Patients with CKD have
high prevalence of comorbid conditions, as documented
in numerous publications [10–13]. These comorbid condi-
tions, such as diabetes and hypertension, are risk factors
for CKD. Despite these easily identified risk groups for
CKD, screening is not routinely carried out, and patients
continue to be referred late to nephrology services [14–
16].
Lack of identification of CKD and, specifically late re-
ferral to specialty care, continues to exist, and is likely a
function of both patient and physician factors [17–19].
The burden of illness. From prevalence studies in dif-
ferent countries, the prevalence of CKD, as defined by
a level of GFR below 60 mL/min/1.71 m2 or urinary ab-
normalities, ranges between 10% and 18% [20, 21]. In
patients over the age of 60, or with comorbid conditions,
the prevalence of CKD is as high as 18% in some reports
[2, 6, 22, 23].
Given these estimates of the high prevalence of CKD,
there is appropriate concern about the ability of the
nephrology community to handle the number of patients.
In an optimally organized system, patients could be iden-
tified and managed by primary care physicians and non-
nephrology specialists in a collaborative manner, thus
offsetting the burden on nephrologists alone.
DEFINING OPTIMAL CARE
Optimal care is care that leads to desired outcomes.
Optimal care of kidney disease patients is therefore care
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which, when implemented reliably, is associated with
delay of progression of CKD; delay of time to dialy-
sis/transplantation; evidence of pre-emptive transplanta-
tion in eligible individuals; delay of progression of CVD;
and reduction in mortality, irrespective of renal replace-
ment therapy.
Strategies that demonstrate consistent results in robust
study designs to delay progression of kidney disease in-
clude reduction in blood pressure, use of angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers, reduction of proteinuria, and glycemic control
in diabetics [24–29]. A detailed review of the evidence for
each of these is beyond the scope of this article.
Additional strategies that address treatments of other
comorbidities and improve quality of life in patients with
CKD include treatment of anemia, attenuation of abnor-
malities of parathyroid hormone, dietary phosphate re-
striction and protein restriction, and maintenance of good
nutritional status.
In addition, many have advocated for strategies that
reduce the inflammation associated with CKD, which ac-
celerates or contributes to accelerated vascular disease.
Although the data for these interventions is less robust,
it is clear that those patients with higher hemoglobin,
who maintain normalized markers of mineral metabolism
(MM) and nutrition, and who have low levels of inflam-
matory markers, have improved outcomes [30–32].
Given the complexity of the care required to detect,
evaluate, and treat patients with CKD, it is clear that to
achieve optimal care of patients with CKD, a coordinated
approach is required. From a population perspective,
this approach includes public awareness and education,
health care system redesign, support of clinical and basic
research, as well as professional education.
From a patient perspective, early identification, risk
factor modification (to delay both progression of CKD
and of CVD), education on treatment options, and longi-
tudinal coordinated multidisciplinary care are required.
The ability to deliver optimal care to individual pa-
tients is inexorably linked to the ability to influence health
care system(s), and population health. These, in turn, are
linked to the ability to conduct appropriate research and
translate findings into clinical practice. An integrated set
of strategies is required to achieve optimal and coordi-
nated care for CKD.
OPTIMAL CARE FOR INDIVIDUALS
The goals of achieving blood pressure levels below
130/80 mm Hg, reducing proteinuria, interrupting the
renin angiotensin system, addressing CVD risk fac-
tors, reducing phosphate and protein consumption, and
maintaining adequate nutrition and education about re-
nal replacement therapy options are well known to all
nephrologists. Nonetheless, the level of care of this pa-
tient group, even when referred in a timely manner re-
mains suboptimal [33, 34].
Early identification is the cornerstone of optimal care,
though debates continue as to what level is appropri-
ate for identification and referral. Early identification
(through automatic reporting of GFR to physicians) and
screening of high-risk populations (persons with diabetes,
CVD, those with a family history of kidney disease, and
those from specific ethnic groups such as African Amer-
icans, aboriginal peoples, and Asians) should be part of
the strategy. Early identification of reduced GFR requires
reliable methods of estimating kidney function. Despite
knowledge about the imprecision of serum creatinine, un-
til recently, there has been an over-reliance on that lab-
oratory test to diagnose kidney disease. Therefore, the
National Kidney Foundation, National Kidney Disease
Education Program, Kidney Disease: Improving Global
Outcomes, and other groups recommend the use of GFR-
estimating equations as the primary method of kidney
function and that clinical laboratories report GFR esti-
mates whenever a serum creatinine is ordered.
Once identified, it is important that both patients and
health care providers understand the care goals and el-
ements and are able to measure individual and patient
outcomes reliably. The use of guidelines, tools, and in-
centives for both patients and practitioners may permit
achievement of these goals. Given the multiplicity of con-
ditions that may lead to CKD, both general practitioner
and specialist education is required. We and others have
demonstrated the utility of coordinated and multidisci-
plinary care models [35–37].
A number of publications have described the utility of
multidisciplinary teams in association with longitudinal
care and protocolized follow-up [27, 35, 38]. The com-
plexity of the management of this patient group requires
a care model which supports it, and the individual prac-
titioner office paradigm is unlikely to be effective in a
complex disease process.
Also, an appropriate method of tracking and evaluat-
ing this complex patient group is required. Informatics
that permit the integration of elements for clinicians, re-
searchers, and administrators are of key importance, but
are presently readily available to the majority of systems.
WHAT WE DO NOT KNOW: THE NEED FOR
ONGOING RESEARCH
The integration of research, education, and clinical care
is imperative if we are to promote optimal care of patients
with recognized kidney disease. Our ability to implement
optimal care programs requires a better understanding of
pathophysiology, pharmacology, and pharmacogenetics,
and the interaction between environment and outcomes.
Without a coordinated approach to the study of CKD and
care delivery, optimal care will remain elusive.
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Data are lacking regarding the outcomes of unreferred
patients, who are identified with lower GFRs through lab-
oratory testing. Furthermore, despite associations of mul-
tiple conventional and nonconventional risk factors for
both progression of CKD and morbidity/mortality, there
are relatively few long-term outcome studies demonstrat-
ing the impact of modification of these risk factors on
progression of disease. Although it is clear that blood
pressure control, interruption of the renin angiotensin
system, and reduction of proteinuria are beneficial, the
impact of multiple strategies implemented together has
not yet been tested, thus the relative utility of each re-
quired further study.
From a basic scientific, mechanistic perspective, much
is now known about progressive vascular and kidney dis-
ease in animal models, but the ability to translate find-
ings into clinical trials has been limited. The unreferred
group of patients offers a remarkable opportunity to
study the natural history of low GFR identified inciden-
tally. Studies are currently ongoing to evaluate outcomes
in this group of patients. Therapeutic strategies need to
be continuously evaluated within the context of clinical
practice.
The need for optimal and coordinated care in patients
with CKD is well known. The delivery of such care is
predicated on an understanding of the need for inte-
gration of health care system delivery, primary preven-
tion, public policy and education, professional education,
and research questions, which facilitate the translation of
knowledge into clinical practice [27, 35, 38–40].
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